From	O
chemotherapy	B:C3665472
to	O
target	O
therapies	O
associated	O
with	O
radiation	O
in	O
the	O
treatment	O
of	O
Non-	O
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
:	O
a	O
durable	O
marriage	O
?.	O

From	O
chemotherapy	O
to	O
target	O
therapies	B:C0087111
associated	O
with	O
radiation	O
in	O
the	O
treatment	O
of	O
Non-	O
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
:	O
a	O
durable	O
marriage	O
?.	O

From	O
chemotherapy	O
to	O
target	O
therapies	O
associated	O
with	O
radiation	O
in	O
the	O
treatment	O
of	O
Non-	B:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
:	O
a	O
durable	O
marriage	O
?.	O

The	O
integration	O
between	O
radiotherapy	B:C0034619
and	O
drugs	O
,	O
from	O
chemotherapy	O
to	O
recently	O
available	O
target	O
therapies	O
,	O
continues	O
to	O
have	O
a	O
relevant	O
role	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	O
and	O
metastatic	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
Non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
.	O

The	O
integration	O
between	O
radiotherapy	O
and	O
drugs	B:C3687832
,	O
from	O
chemotherapy	O
to	O
recently	O
available	O
target	O
therapies	O
,	O
continues	O
to	O
have	O
a	O
relevant	O
role	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	O
and	O
metastatic	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
Non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
.	O

The	O
integration	O
between	O
radiotherapy	O
and	O
drugs	O
,	O
from	O
chemotherapy	B:C3665472
to	O
recently	O
available	O
target	O
therapies	O
,	O
continues	O
to	O
have	O
a	O
relevant	O
role	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	O
and	O
metastatic	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
Non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
.	O

The	O
integration	O
between	O
radiotherapy	O
and	O
drugs	O
,	O
from	O
chemotherapy	O
to	O
recently	O
available	O
target	O
therapies	B:C0087111
,	O
continues	O
to	O
have	O
a	O
relevant	O
role	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	O
and	O
metastatic	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
Non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
.	O

The	O
integration	O
between	O
radiotherapy	O
and	O
drugs	O
,	O
from	O
chemotherapy	O
to	O
recently	O
available	O
target	O
therapies	O
,	O
continues	O
to	O
have	O
a	O
relevant	O
role	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	O
and	O
metastatic	O
Non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
Non	O
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
.	O

The	O
integration	O
between	O
radiotherapy	O
and	O
drugs	O
,	O
from	O
chemotherapy	O
to	O
recently	O
available	O
target	O
therapies	O
,	O
continues	O
to	O
have	O
a	O
relevant	O
role	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	O
and	O
metastatic	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
(	O
Non	B:C0007131
-	I:C0007131
small	I:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
)	O
.	O

Aim	O
of	O
the	O
present	O
review	B:C0282443
is	O
to	O
evaluate	O
the	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

Aim	O
of	O
the	O
present	O
review	O
is	O
to	O
evaluate	B:C0220825
the	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

Aim	O
of	O
the	O
present	O
review	O
is	O
to	O
evaluate	O
the	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	B:C3687832
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

Aim	O
of	O
the	O
present	O
review	O
is	O
to	O
evaluate	O
the	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	B:C0034619
.	O

We	O
searched	O
Medline	B:C0025141
,	O
Google	O
Scholar	I:C0242356
,	O
PubMed	O
,	O
ProQuest	O
Dissertation	I:C0242356
,	O
and	O
Theses	O
databases	O
for	O
reports	O
published	O
in	O
English	O
.	O

We	O
searched	O
Medline	O
,	O
Google	B:C0242356
Scholar	I:C0242356
,	O
PubMed	O
,	O
ProQuest	O
Dissertation	I:C0242356
,	O
and	O
Theses	O
databases	O
for	O
reports	O
published	O
in	O
English	O
.	O

We	O
searched	O
Medline	O
,	O
Google	O
Scholar	I:C0242356
,	O
PubMed	B:C1138432
,	O
ProQuest	O
Dissertation	I:C0242356
,	O
and	O
Theses	O
databases	O
for	O
reports	O
published	O
in	O
English	O
.	O

We	O
searched	O
Medline	O
,	O
Google	O
Scholar	I:C0242356
,	O
PubMed	O
,	O
ProQuest	B:C0242356
Dissertation	I:C0242356
,	O
and	O
Theses	O
databases	O
for	O
reports	O
published	O
in	O
English	O
.	O

We	O
searched	O
Medline	O
,	O
Google	O
Scholar	I:C0242356
,	O
PubMed	O
,	O
ProQuest	O
Dissertation	I:C0242356
,	O
and	O
Theses	O
databases	B:C0242356
for	O
reports	O
published	O
in	O
English	O
.	O

We	O
searched	O
Medline	O
,	O
Google	O
Scholar	I:C0242356
,	O
PubMed	O
,	O
ProQuest	O
Dissertation	I:C0242356
,	O
and	O
Theses	O
databases	O
for	O
reports	B:C0684224
published	O
in	O
English	O
.	O

A	O
study	B:C2603343
was	O
included	O
when	O
it	O
reported	O
on	O
cancer	O
-	I:C0034619
related	I:C0034619
radiotherapy	I:C0034619
and	O
included	O
patients	O
with	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
treated	O
with	I:C0332293
chemo	O
and	O
/	O
or	O
target	O
therapies	O
.	O

A	O
study	O
was	O
included	O
when	O
it	O
reported	O
on	O
cancer	B:C0034619
-	I:C0034619
related	I:C0034619
radiotherapy	I:C0034619
and	O
included	O
patients	O
with	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
treated	O
with	I:C0332293
chemo	O
and	O
/	O
or	O
target	O
therapies	O
.	O

A	O
study	O
was	O
included	O
when	O
it	O
reported	O
on	O
cancer	O
-	I:C0034619
related	I:C0034619
radiotherapy	I:C0034619
and	O
included	O
patients	O
with	O
Non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
treated	O
with	I:C0332293
chemo	O
and	O
/	O
or	O
target	O
therapies	O
.	O

A	O
study	O
was	O
included	O
when	O
it	O
reported	O
on	O
cancer	O
-	I:C0034619
related	I:C0034619
radiotherapy	I:C0034619
and	O
included	O
patients	O
with	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
treated	B:C0332293
with	I:C0332293
chemo	O
and	O
/	O
or	O
target	O
therapies	O
.	O

A	O
study	O
was	O
included	O
when	O
it	O
reported	O
on	O
cancer	O
-	I:C0034619
related	I:C0034619
radiotherapy	I:C0034619
and	O
included	O
patients	O
with	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
treated	O
with	I:C0332293
chemo	B:C3665472
and	O
/	O
or	O
target	O
therapies	O
.	O

A	O
study	O
was	O
included	O
when	O
it	O
reported	O
on	O
cancer	O
-	I:C0034619
related	I:C0034619
radiotherapy	I:C0034619
and	O
included	O
patients	O
with	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
treated	O
with	I:C0332293
chemo	O
and	O
/	O
or	O
target	O
therapies	B:C0087111
.	O

Review	B:C0282443
articles	I:C0282443
were	O
excluded	O
from	O
the	O
analysis	O
.	O

Review	O
articles	I:C0282443
were	O
excluded	O
from	O
the	O
analysis	B:C0936012
.	O

Expert	O
commentary	O
:	O
Chemo	O
-	O
radiotherapy	O
still	O
represents	O
the	O
standard	O
of	O
choice	O
in	O
locally	O
advanced	O
Non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
,	O
while	O
to	O
date	O
the	O
addition	O
of	O
target	O
therapies	O
to	O
chemo	O
-	O
radiotherapy	O
did	O
not	O
demonstrate	O
any	O
robust	O
advantage	O
in	O
this	O
stage	O
of	O
disease	O
.	O

Expert	O
commentary	O
:	O
Chemo	O
-	O
radiotherapy	O
still	O
represents	O
the	O
standard	O
of	O
choice	O
in	O
locally	O
advanced	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
,	O
while	O
to	O
date	O
the	O
addition	O
of	O
target	O
therapies	B:C0087111
to	O
chemo	O
-	O
radiotherapy	O
did	O
not	O
demonstrate	O
any	O
robust	O
advantage	O
in	O
this	O
stage	O
of	O
disease	O
.	O

Considering	O
the	O
absence	O
of	O
randomized	B:C0206035
controlled	I:C0206035
trials	I:C0206035
,	O
the	O
role	O
of	O
target	O
therapies	O
in	O
early	O
stage	O
adjuvant	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
is	O
not	O
yet	O
recommended	O
in	O
clinical	O
practice	I:C0282574
.	O

Considering	O
the	O
absence	O
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
,	O
the	O
role	O
of	O
target	O
therapies	B:C0087111
in	O
early	O
stage	O
adjuvant	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
is	O
not	O
yet	O
recommended	O
in	O
clinical	O
practice	I:C0282574
.	O

Considering	O
the	O
absence	O
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
,	O
the	O
role	O
of	O
target	O
therapies	O
in	O
early	O
stage	O
adjuvant	O
Non-small	B:C0007131
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
is	O
not	O
yet	O
recommended	O
in	O
clinical	O
practice	I:C0282574
.	O

Considering	O
the	O
absence	O
of	O
randomized	O
controlled	I:C0206035
trials	I:C0206035
,	O
the	O
role	O
of	O
target	O
therapies	O
in	O
early	O
stage	O
adjuvant	O
Non-small	O
cell	I:C0007131
lung	I:C0007131
cancer	I:C0007131
is	O
not	O
yet	O
recommended	O
in	O
clinical	B:C0282574
practice	I:C0282574
.	O

On	O
the	O
contrary	O
,	O
in	O
the	O
setting	O
of	O
oligometastatic	B:C0027627
and	O
oligoprogressive	O
disease	I:C0027627
,	O
new	O
molecules	O
demonstrated	O
to	O
be	O
safe	O
and	O
effective	O
,	O
opening	O
to	O
a	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

On	O
the	O
contrary	O
,	O
in	O
the	O
setting	O
of	O
oligometastatic	O
and	O
oligoprogressive	B:C0027627
disease	I:C0027627
,	O
new	O
molecules	O
demonstrated	O
to	O
be	O
safe	O
and	O
effective	O
,	O
opening	O
to	O
a	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

On	O
the	O
contrary	O
,	O
in	O
the	O
setting	O
of	O
oligometastatic	O
and	O
oligoprogressive	O
disease	I:C0027627
,	O
new	O
molecules	O
demonstrated	O
to	O
be	O
safe	O
and	O
effective	O
,	O
opening	O
to	O
a	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	B:C3687832
and	O
new	O
modalities	O
of	O
radiotherapy	O
.	O

On	O
the	O
contrary	O
,	O
in	O
the	O
setting	O
of	O
oligometastatic	O
and	O
oligoprogressive	O
disease	I:C0027627
,	O
new	O
molecules	O
demonstrated	O
to	O
be	O
safe	O
and	O
effective	O
,	O
opening	O
to	O
a	O
promising	O
and	O
emerging	O
application	O
of	O
the	O
best	O
interaction	O
between	O
new	O
drugs	O
and	O
new	O
modalities	O
of	O
radiotherapy	B:C0034619
.	O

